

# Advancing haemophilia management: N8-GP efficacy and safety in patients of all ages



Thursday, 3 February 2022; 18:00 – 19:00 CET

Chair: **Pratima Chowdary**

<b>Welcome &amp; introduction</b>	Pratima Chowdary London, UK
<b>Meeting patient needs: N8-GP long-term efficacy and dose individualisation</b>	Pratima Chowdary
<b>Treatment of previously untreated patients (PUPs) with N8-GP: pathfinder6 results</b>	Christoph Male Vienna, Austria
<b>pathfinder6 data in perspective: Insights from the PedNet registry</b>	Marijke van den Berg Baarn, The Netherlands
<b>Q&amp;A, discussion &amp; final remarks</b>	All and Chair

Symposium recording available on-demand, within the virtual platform, following the conclusion of the congress.

This symposium will focus on the most-recent advances in the management of previously treated patients with N8-GP (turoctocog alfa pegol), including long-term efficacy and dose individualisation data, and present the efficacy and safety of N8-GP for treatment of previously untreated patients (PUP).

Furthermore, PUP data will be discussed in a broader perspective with insights from the PedNet registry.